AMICUS THERAPEUTICS, INC. — Director's Dealing 2022

Apr 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2022-03-15

Reporting Person: Campbell Bradley L (Director, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-15	Common Stock	A	104603	—	Acquired	689618	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-15	Stock Options (right to buy)	$8.95	A	187970	Acquired	2032-03-15	Common Stock (187970)	Direct

Footnotes

F1: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.

F2: The Restricted Stock Units will vest in four equal annual installments beginning on March 15, 2023.

F3: These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.